Launch Date
07/24/2023 at 4:00 am EST
Credit Amount
0.25
Credit Expires
07/24/2024
Narcolepsy consists of two types: type 1 (NT1, or narcolepsy with cataplexy), and type 2 (NT2, or narcolepsy without cataplexy). Despite differences in cataplexy, both are associated with excessive daytime sleepiness (EDS) and disrupted night-time sleep, which can lead to significant impacts for patients. In pediatric populations, children with narcolepsy tend to have poor performance in school, which often worsens as subject matter becomes more advanced. Children with narcolepsy also suffer from depression and helplessness, which can lead to loss of self-esteem and negative interactions with classmates. Overall, children with narcolepsy perform significantly lower in health-related QoL (HRQoL) studies than those without narcolepsy. Clinicians must understand narcolepsy’s impact on patients in order to provide necessary treatment.
In this CME Snack, expert faculty will discuss how to better identify the impact of symptoms on QoL and work, school, and/or psychosocial functioning for pediatric and adult patients with narcolepsy.
Analyze the impact of narcolepsy and its symptoms on the QoL and functioning of patients and their families/caregivers.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Bogan reports the following financial relationships:
Consultant: Avadel; Axsome Therapeutics, Inc.; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; Oventus; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Apnimed; Avadel; Bayer; Bresotec Medical; Eisai Inc.; Fisher Paykel Healthcare; FRESCA Medical; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; NLS Pharmaceutics; Philips; Roche; Sanofi; Sommetrics, Inc.; Suven Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc.
Speakers Bureau: Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals US Inc.; and Jazz Pharmaceuticals, Inc.
Dr. Morse reports the following financial relationships:
Advisory Board: Alkermes; Avadel; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Coverys Community Healthcare Foundation; Jazz Pharmaceuticals, Inc.; and ResMed Foundation
Research Support: Geisinger Health Plan; Jazz Pharmaceuticals, Inc.; and UCB, Inc.
Speakers Bureau: Jazz Pharmaceuticals, Inc.
Employment: DAMM Good Sleep, LLC (CEO)
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
SN-210-072423-43